Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026)
Nurix Therapeutics (NRIX) reported Income from Continuing Operations of -$89.54 million for fiscal Q2 2026 (quarter ended May 31, 2026), compared with -$43.46 million a year earlier.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Over the twelve months ended May 31, 2026, Nurix Therapeutics' Income from Continuing Operations came in at -$341.35 million; for FY2025 (ended Nov 30, 2025), it came in at -$264.46 million.
- By fiscal year, Income from Continuing Operations came in at -$193.57 million in FY2024, -$143.95 million in FY2023, -$180.36 million in FY2022 and -$117.19 million in FY2021.
- The fiscal Q2 2026 figure ranks as the lowest quarterly Income from Continuing Operations in data going back to fiscal Q3 2019.
- Per Business Quant data, the three fiscal quarters before Q2 2026 came in at -$87.17 million (Q1 2026), -$78.22 million (Q4 2025) and -$86.42 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Nurix Therapeutics | 2.46 Bn | 452.73 Mn | - | -89.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -89.54 Mn |
| Feb 28, 2026 | -87.17 Mn |
| Nov 30, 2025 | -78.22 Mn |
| Aug 31, 2025 | -86.42 Mn |
| May 31, 2025 | -43.46 Mn |
| Feb 28, 2025 | -56.35 Mn |
| Nov 30, 2024 | -58.55 Mn |
| Aug 31, 2024 | -48.96 Mn |
| May 31, 2024 | -44.55 Mn |
| Feb 29, 2024 | -41.52 Mn |
| Nov 30, 2023 | -41.96 Mn |
| Aug 31, 2023 | -36.98 Mn |
| May 31, 2023 | -24.28 Mn |
| Feb 28, 2023 | -40.73 Mn |
| Nov 30, 2022 | -46.72 Mn |
| Aug 31, 2022 | -45.71 Mn |
| May 31, 2022 | -45.40 Mn |
| Feb 28, 2022 | -42.53 Mn |
| Nov 30, 2021 | -37.69 Mn |
| Aug 31, 2021 | -28.84 Mn |
API Access
Nurix Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NRIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "NRIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NRIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();